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Abstract
Background: The effect of peer support on virologic and immunologic treatment outcomes among HIVinfected
patients receiving antiretroviral therapy (ART) was assessed in a cluster randomized controlled trial in Vietnam.
Methods: Seventy-one clusters (communes) were randomized in intervention or control, and a total of 640 patients
initiating ART were enrolled. The intervention group received peer support with weekly home-visits. Both groups
received first-line ART regimens according to the National Treatment Guidelines. Viral load (VL) (ExaVir™ Load) and
CD4 counts were analyzed every 6 months. The primary endpoint was virologic failure (VL >1000 copies/ml).
Patients were followed up for 24 months. Intention-to-treat analysis was used. Cluster longitudinal and survival
analyses were used to study time to virologic failure and CD4 trends.
Results: Of 640 patients, 71% were males, mean age 32 years, 83% started with stavudine/lamivudine/nevirapine
regimen. After a mean of 20.8 months, 78% completed the study, and the median CD4 increase was 286 cells/μl.
Cumulative virologic failure risk was 7.2%. There was no significant difference between intervention and control
groups in risk for and time to virologic failure and in CD4 trends. Risk factors for virologic failure were ART-non-
naïve status [aHR 6.9;(95% CI 3.2–14.6); p < 0.01]; baseline VL ≥100,000 copies/ml [aHR 2.3;(95% CI 1.2–4.3); p < 0.05]
and incomplete adherence (self-reported missing more than one dose during 24 months) [aHR 3.1;(95% CI 1.1–8.9);
p < 0.05]. Risk factors associated with slower increase of CD4 counts were: baseline VL ≥100,000 copies/ml [adj.sq.
Coeff (95% CI): −0.9 (−1.5;−0.3); p < 0.01] and baseline CD4 count <100 cells/μl [adj.sq.Coeff (95% CI): −5.7 (−6.3;−5.4);
p < 0.01]. Having an HIV-infected family member was also significantly associated with gain in CD4 counts [adj.sq.Coeff
(95% CI): 1.3 (0.8;1.9); p < 0.01].
Conclusion: There was a low virologic failure risk during the first 2 years of ART follow-up in a rural low-income setting
in Vietnam. Peer support did not show any impact on virologic and immunologic outcomes after 2 years of follow up.
Trial registration: NCT01433601.
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Background
Globally, the number of HIV-infected people receiving
antiretroviral therapy (ART) was about 14.9 million by
end of 2014, most of them living in low- and middle-
income countries [1–3]. To ensure the sustainability of
ART programs in resource-limited settings, it is essential
to find effective ways to maintain patients on first-line
regimens as long as possible as adherence to ART has a
major influence on treatment failure and the develop-
ment of HIV drug resistance [1, 4–6]. However, the
provision of ART in low-resource settings remains chal-
lenging due to the shortage of human resources [3]. The
World Health Organization (WHO) and the United
States President’s Emergency Plan for AIDS Relief (PEP-
FAR) advocated a strategy to mobilize the involvement
of people living with HIV (PLHIV) through task shifting
among health workforce team [7]. WHO/UNAIDS pro-
posed the “Treatment 2.0” initiative that aimed to reach
and sustain universal access to treatment and capitalize
on the preventive benefit of ART through five high-
priority goals: 1) optimize drug regimens; 2) provide
point of care diagnosis; 3) reduce costs; 4) adapt delivery
systems and 5) mobilize communities [3, 8].
In sub-Saharan Africa, peer support and home-based
care have become part of the HIV comprehensive care
and treatment package [9–11], in which the role of peer
support is acknowledged as an essential activity for treat-
ment success [12]. A recent randomized controlled trial
(RCT) in Uganda showed that community-based peer
health worker intervention had an effect on reducing
virologic failure risk after 96 weeks of treatment [13]. A
meta-analysis review indicates that peer education pro-
grams in developing countries are moderately effective
at improving behavioral outcomes but show no signifi-
cant impact on biological outcomes [14]. On the other
hand, in most Asian countries, where the HIV epidemic
is in a concentrated stage targeting the high risk popula-
tion such as injecting drug users (IDUs) and sex workers,
the adherence support may pose different challenges [15].
Hence the impact of peer support in Asian countries on
virologic failure has not been proven.
In Vietnam, the ART programs have been rapidly scal-
ing up with the support from PEPFAR and Global Fund
to fight AIDS, Tuberculosis and Malaria (GFATM). By
the end of 2010, more than 82,700 people had access to
free ART (70% coverage) [16]. According to the revised
National Guidelines [17], VL testing is indicated only for
assessing patients suspected of failing the first-line treat-
ment [18, 19]. A qualitative study conducted among 48
PLHIV about adherence obstacles encountered during
ART, methods that patients used to enhance adherence,
treatment support structures, and attitudes toward home
delivery of ART showed that stigma was identified as a
strong barrier to ART adherence and that patients
seeked more community-based support, preferably from
PLHIV who had received sufficient training. Home deliv-
ery of ART medications was seen as undesirable by
PLHIV, who feared that it might increase stigma and dis-
crimination [20]. We have shown that the community-
based peer support had an impact on reducing stigma
and discrimination, increasing the access to counseling
and testing, improving the quality of life, and enhancing
adherence to ART among ART patients presenting at
clinical stages 3 and 4 at baseline. However, community-
based peer support had no impact on quality of life
among ART patients enrolled at clinical stages 1 and 2
[21]. However, the impact of peer support on treatment
outcomes, especially on virologic failure, has not yet
been assessed.
We conducted this study with the aim of testing the
hypothesis that peer support intervention has an impact
on virologic and immunologic responses in HIV-infected
patients initiated on first-line ART regimens in a rural
resource-limited setting in Quang Ninh, Vietnam. This
approach will result in evidence-based ART strategies
for large populations in low income and low prevalence




Quang Ninh province is located along northeastern
Vietnam with a population of 1.1 million and an area of
6100 km2. Quang Ninh has 14 cities/districts, in which
Ha Long City is the biggest (20 communes, 221,000 ha-
bitants). It is also home to the famous World Heritage
Site, Ha Long Bay. Coal mining, fisheries, and tourism
are the main industries.
HIV prevalence in Quang Ninh was about 1%, of
which 55% of PLHIV were IDUs (reported by Provincial
AIDS Committee-2006). Patients were recruited from
four outpatient clinics (OPC): Ha Long CDC-LifeGap
clinic, located in the provincial hospital in Ha Long City
and supported by PEPFAR which has more resources, and
three Global Fund supported clinics (Uong Bi, Ha Long
Health Center and Yen Hung). These were the only clinics
in the districts and hence there was a low risk for selection
bias from both patients and the project.
The cluster randomized controlled trial “Directly
Observed Therapy for Antiretrovirals” (DOTARV),
registration number NCT01433601 was carried out in 4
districts/cities (Ha Long, Uong Bi, Dong Trieu, Yen
Hung). The reasons for choosing these 4 districts/cities
were: (i) community based care was not available, (ii)
these were adjacent districts, and (iii) each had high
HIV prevalence. To minimize contamination (that the
effect of peer support to patients in the intervention
group would also influence the control groups due to
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personal relationships among patients in intervention
and control group), the unit of randomization and analysis
was the cluster (commune).
Participant recruitment and study procedures
This trial was conducted between July 2007 through
November 2011, with 2 years of patient recruitment
and 2 years of follow-up.
According to the National Guidelines (2005) [22],
HIV-infected individuals were eligible to be registered
for free at an ART clinic if they: i) were confirmed HIV
positive, ii) possessed valid civil registration information
(home address and telephone), iii) had a family member
who could act as a supporter, and iv) agreed to enroll
and to be followed up in the ART program. Each clinic
was staffed with two medical doctors, one adherence
counselor, one reception nurse, one phlebotomy nurse,
one pharmacist, and one volunteer who was a person
living with HIV (PLHIV). The staff were trained on basic
and advanced HIV care and treatment and certified by
Ministry of Health.
All registered patients received a set standard of care,
co-trimoxazole prophylaxis, and were assessed at base-
line for socio-economic situations. They were also eval-
uated clinically, undergoing WHO HIV clinical staging,
as well as screening for tuberculosis (TB), viral hepatitis
B and C, and opportunistic infections (OIs). Their CD4
counts were taken, and those who were eligible for
ART (clinical stage 4 with CD4 count <200 cells/μl or
clinical stage 3 with CD4 count <350 cells/μl) were put
on the waiting list for ART and selected on a “first
come, first served” basis. Patients diagnosed with OIs
were treated by OI medications. If TB was diagnosed,
patients were referred to the provincial TB hospital in
Ha Long City. They were initiated on ART after receiv-
ing two months of intensive TB treatment. Every
month, a range of 15 to 20 patients per clinic, from
both groups, were selected, based on the “first come,
first served” recruitment list, to attend a pre-ART
readiness training on both an individual and group
basis. Each clinic received a quota of patients that were
planned to initiate ART stipulated by the local health
authorities. The training included HIV basics, stigma
and discrimination, positive living, transmission pre-
vention, ART regimens and treatment adherence. A
family member also attended the training and became
an adherence supporter for the patient. ARV drugs
were provided in pre-packed dosage form for conveni-
ence and to promote adherence. The first-line ARV
regimens included two nucleoside reverse transcriptase
inhibitors (NRTIs): stavudine (d4T) or zidovudine
(AZT) plus lamivudine (3TC) combined with one non-
nucleoside reverse transcriptase inhibitor NNRTI:
nevirapine (NVP) or efavirenz (EFV). All care and
medications were provided free of charge.
Patients who participated in the study were selected
from the pre-ART waiting list. All patients fulfilling the
criteria and planned for ART were asked for their con-
sent to take part in the trial. The patients were informed
about the trial by study doctors. The patients, if they
agreed to participate, signed the informed consent form.
Study doctors would assign patients to either the inter-
vention group or the control group based on the com-
mune where they were living from one of a total of 71
communes in 4 districts. The ratio for intervention: con-
trol communes was 36:35 (1:1). The clusters in all four
districts were randomized by a statistician who was not
involved in the study and were matched according to
the following criteria (i) urban vs. rural (official registra-
tion, based on population density), (ii) vicinity to the
clinic (more or less than 5 km), and (iii) population
(more or less than 25,000). The randomization of
matched clusters was through a computer software by a
statistician not directly involved in the project with no
local acquaintance. This study followed an open label
cluster randomized controlled trial design.
Inclusion criteria were (i) confirmed HIV-infected, (ii)
reported as ART-naïve, (iii) resident in any of the four
study districts, (iv) age 18 years or older, (v) eligible for
ART according to the National Guidelines (2005), CD4
count <200 cells/μl or clinical stage 4, or clinical stage 3
with CD4 count <350 cells/μl, (vi) willing to submit to
follow ups and to receive adherence support by a peer-
supporter, and (vii) signed a written informed consent.
Exclusion criteria were (i) pregnancy or (ii) mental
illness.
Intervention strategy: peer-support
The peer-support intervention strategy was home-based
adherence counseling conducted by peer supporters who
were HIV-infected individuals on ART and nominated
by fellow patients and health care staff at each clinic site.
The qualifications needed for peer-supporters were (i)
social ability, (ii) good ART adherence for at least 6
months, (iii) high school graduation, (iv) willingness to
participate in the study and (v) passed the qualifying test
after the training. The OPC’s and local health authorities
proposed candidates that fulfilled the selection criteria’s.
The proportion of the peer-supporters to the number of
recruited patients living in each district was about 1:20,
meaning that one supporter would support a maximum
of 20 patients. The peer-supporters received 1-week’s
training conducted by project researchers on basic HIV
care and support, communication and counseling skills,
and the process for completing the adherence checklist
form. Two 1-week refresher trainings were provided
yearly throughout the study.
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The standard support performed by peer-supporters
included home-based visits and completion of the ad-
herence checklist form, in which patients were asked
about their wellbeing, OI and adverse drug reaction
(ADR) signs and symptoms, the times at which they took
the pills, any doses missed for last 4 days, barriers to ad-
herence, and pill count. If an incomplete adherence was
reported, the peer supporter would counsel and discuss
with the patients and family supporters how to improve
the adherence.
The initial schedule of support was twice a week in
the first 2 months, then once a week when patients’
adherence passed assessments. Additional visits were
provided if patients were sick or had a serious ADR or a
history of poor adherence. A telephone call was used to
arrange a 15- to 30-min appointment place in advance
between peer supporters and patients to minimize wast-
ing time or to ensure confidentiality for patients who
feared disclosure of their HIV status to others in their
surroundings. Due to the associated stigma, the supporters
did not wear a work outfit for home visits to minimize the
patient’s fear of stigma developing from others in their sur-
roundings. Before being recruited for the study, patients
were made aware that being a part of the study would re-
quire them to disclose their HIV status. They were warned
about the possibility of stigmatization. If patients were not
comfortable with that possibility or if they experienced any
harm during the study, patients would choose not to be a
part of the study. This was monitored during the OPC
visits. To ensure satisfactory work by the peer supporters,
bi-weekly supervision of peer-support activities was con-
ducted by a peer-support group leader in each district.
Monthly supervision meetings of peer-support activities
were performed by project researchers.
Patients in both intervention and control groups re-
ceived a set standard of care and treatment according to
the National Guidelines [22] including pre-ART initi-
ation, which consisted of three ART adherence training
sessions in both individual and group settings. Health
checks, blood sampling and drug dispensations were
carried out on a monthly basis at the OPC. Selfreported
adherence for the last-4-day period was assessed quarterly
by an adherence counseling staff member. CD4 counts
were run at baseline and every 6 months by using the
Partec CyFlow® system in Uong Bi hospital and the Becton
Dickinson® system in Quang Ninh provincial hospital.
Viral load and CD4 count screening
The Exavir™ Load, an enzyme-linked immune-sorbent
assay (ELISA)-based VL quantification test (Cavidi AB,
Uppsala, Sweden [23, 24]), was used in Vietnam for the
first time to monitor the virologic outcomes for all par-
ticipants every 6 months for 24 months of the study.
The detection limits range from 200 to 410,000 copies/
ml [25]. Details on the laboratory procedures of ExaVir
Load assay were reported in an earlier publication [26].
CD4 counts were run at baseline and every 6 months
by the Partec CyFlow® in Uong Bi hospital and the
Becton Dickinson® in Quang Ninh provincial hospital.
Adherence assessment
In both the intervention and control groups, patients were
assessed by health care staff at the clinic for adherence
every 3 months using an adherence checklist modified
from the contextualized Adult AIDS Clinical Trials Group
(AACTG) adherence instrument [27]. In this checklist, pa-
tients self-reported any OI and ADR symptoms, whether
they had missed any doses during the last 4 days, or if they
had incorrectly measured their pill-count.
Incomplete adherence was defined as the patient stat-
ing in the 3-month adherence checklist form that he or
she missed more than one dose (2 or more; either in
morning or evening) of ARV during the 24 months of
their follow-up time.
Complete adherence was defined as the patient self-
reporting in the 3-month adherence checklist form that
he or she did not miss any dose or just one dose (either
in the morning or evening) of ARV drugs during the
24 months of their follow-up time.
Definitions
Virologic failure was defined as either (i) primary viro-
logic failure if VL >1000 copies/ml after 6 months of
ART initiation or (ii) secondary virologic failure if VL
was undetectable (<200 copies/ml) after 6 months of
ART initiation and then became >1000 copies/ml at any
time point during the follow-up. Virologic failure pa-
tients were reported to the attending medical doctors
and adherence counselors in their respective clinics.
Then a follow-up VL test was repeated after at least one
month but within 3 months of the initial virologic fail-
ure. If VL remained >1000 copies/ml, the patient was
then reported to an OPC doctor and flagged for a con-
firmatory PCR VL. According to VGHADT (2009) [17],
patients were eligible for switching to second-line ther-
apy if they meet the criteria of clinical or immunologic
failure and, if available, they have been confirmed to
have a PCR VL >5000 copies/ml. Additionally, patients
with detectable viral load in the intervention group
received an intensive adherence counseling support by
the peer supporters through the provision of two to
three home visits per week.
Death events were ascertained by a medical doctor
confirmation or, in the intervention group, by a peer-
supporter through telephone calls or home visits. In
cases of a missing follow-up, event of death was confirmed
through telephone calls to family members and home
visits by peer supporters.
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Lost-to-follow-up was defined as: when the patient was ei-
ther arrested or placed in a compulsory drug rehabilitation
center for 24 months due to active heroin use, thus disab-
ling follow-up during the study period; or when the patient
did not show up at the OPC for 3 consecutive visits; or if
the patient voluntarily withdrew from the study. Patients in
both groups were called to determine the reason of their
lost-to-follow-up.
Transferred patients were defined as those who were
confirmed as being registered with another OPC which
was outside of our four study sites.
Changed-regimen was defined as a patient who had to
change one of the three ARV drugs in the regimen for
any clinical reason (ADRs or TB co-infection treatment)
during ART.
Study endpoints
The primary endpoint was the risk of virologic failure
during 24 months of follow-up.
The secondary endpoint was the time course of CD4
cell counts over the period of 24 months of follow up.
Data collection
Data were collected as follows: i) socio-economic situ-
ation at baseline, ii) clinical and laboratory data at
baseline and follow-up visits every 6 months, (iii) self-
reported adherence form was administered by health
staff every 3 months, and (iv) ART adherence forms
completed by peer supporters.
Sample size
Patients were allocated to the intervention group ac-
cording to a randomization of clusters (communes)
where patients lived. Sample size for cluster randomized
trial was calculated by using formulas in [28]. Assuming
the baseline figure for virologic failure risk in the inter-
vention group equal to 5%, and equal to 15% in the con-
trol group, a power of 80%, the significance level of the
two-sided alpha 0.05, a randomization ratio of 1 (inter-
vention):1 (control), an estimation of intraclass coeffi-
cient equal to 0.1, a number of clusters in each group
equal to 35 and adding 30% for lost-to-follow-up, the
minimum needed sample size was 638 patients (about
319 patients per study arm).
Statistical analysis
Intention-to-treat analysis was used to calculate virologic
failure risk.
Mean, median and standard deviation were used for
summarizing numerical variables, frequencies, and per-
centages for the categorical variables.
Chi-square tests were performed to compare interven-
tion and control groups for demographic and clinical
characteristics at baseline.
Crude relative risks (RR) at 6, 12, 18, and 24 months
were calculated to assess the relationship between vi-
rologic failure and intervention/control groups at dif-
ferent time points.
Kaplan-Meier curves were produced, together with a
log-rank test, to compare time to virologic failure between
control and intervention group. Cox proportional hazards
frailty model, adjusting for potential confounders, was used
to analyze the hazard rate among the intervention and
control groups, taking into account the clustered nature of
the data. Schoenfeld residuals were used for checking
the proportional hazard assumptions; no timedependent
variables were considered.
The final model was selected using a forward- stepwise
selection with a p-value cut-off for entering the model
equal to 0.1. A likelihood-ratio test was used for testing
the null hypothesis of no variance of the frailty effects.
CD4 count trends over time were analyzed using a
mixed-effects model with a polynomial function of time
in the fixed component. Due to the hierarchical struc-
ture of the data, random effects of clusters (communes,
individual and measurement) were incorporated into the
model. Square-root transformation was used for the
CD4 count approximating a normal distribution [29].
Once the data was collected, the models were adjusted
for the following variables: randomized groups (control
vs intervention); age (≥35 vs <35 years); gender (male vs
female); WHO clinical stage (stage 1 and 2 vs stage 3
and 4); baseline VL (≥100,000 copies/ml vs <100,000
copies/ml) and baseline CD4 counts (≥100 cells/μl vs
<100 cells/μl); ART-naïve status (yes vs no); history of
IDU (yes vs no); TB history (yes vs no); history of OIs
(yes vs no); having an HIV-infected family member (yes
vs no); receiving ART in Halong CDC clinic (yes vs no),
changed ART regimen (yes vs no); and incomplete
adherence (yes vs no). Since there was a significant
difference between the groups receiving ART in Halong
CDC clinic, it was especially important to adjust for this
difference.
The above mentioned demographic and clinical
characteristics at baseline were tested as independent
variables both in the survival and mixed effects models.
P-values less than 0.05 were considered significant in
the final model. The statistical analyses were performed
using STATA version 12.0 (College Station, StataCorp LP,
TX, USA).
Results recruitment of the cohort
During the period of July 2007 through November 2009,
a total of 640 HIV-infected participants (332 interven-
tion patients and 308 control patients) were enrolled
from 59 communes (30 intervention communes and 29
control communes). As 12 of the communes had no
participants, these were removed from the analysis. Ha
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Long City had the majority of patients (418; 65%), then
Uong Bi (87; 14%), Dong Trieu (71; 11%) and Yen Hung
(64; 10%). The distribution of patients in the four study
clinics were: Ha Long CDC Life-Gap clinic (307; 48%);
The Uong Bi Hospital clinic included patients from
Dong Trieu district (181; 28%); Ha Long Health Center
clinic (106; 17%) and Yen Hung clinic (46; 7%). On
average, each commune had 11 patients. However, the
number of patients was not distributed equally among
communes: the Cao Xanh commune in Ha Long City
has the highest number of patients (46) while 12 com-
munes had only 1 patient each and another 12 had no
patients enrolled in the study (Table 1). A sensitivity
analysis was done and found that the inclusion of the 12
communes with 1 patient each did not invalidate the
findings of the study (data not shown).
After conducting a one-week pilot training session, we
selected 14 qualified peer supporters (8 females, 6
males), aged between 25 and 44 years. The number of
supporters was proportional to the number of interven-
tion patients in each district/city. Seven peer supporters
were based in Ha Long (191 patients), 3 in Uong Bi (51
patients), 2 in Dong Trieu (56 patients) and 2 in Yen
Hung (34 patients). Each peer supporter was responsible
for visiting between 10 and 20 patients.
By the end of the study, mean follow-up time was
20.4 ± 7.2 months (20.5 ± 7.2 and 20.4 ± 7.3 months for
intervention and control groups, respectively), 78% (501/
640) of patients remained on ART, 11% (70/640) were
dead, 10% (64/640) were lost-to-follow-up and 1% (5/
640) had transferred to other clinics. Among the lost-to-
follow-up patients, 17 (27%) had voluntarily withdrawn,
7 (11%) did not show up for three consecutive visits and
40 (62%) were arrested and put in rehabilitation centers
due to injecting heroin. Eleven patients were arrested
during the ART treatment, however, they had continu-
ous access to ART and then resumed their ART at the
clinics after being released from the rehabilitation center,
therefore they were not considered lost-to-follow-up.
The distribution of retention in care, dead, lostto-follow-
up, and transferred patients were equally distributed in
both intervention and control groups (Fig. 1).
Table 2 described the characteristics of the cohort
divided by control and intervention groups at baseline
with no significant differences observed between the two
groups, apart from in those patients from the Ha Long
CDC clinic.
Clinical outcome
At month 24, clinical outcomes improved, as mean body
weight increased from 50.2 ± 7.3 kg at baseline to 53.7 ±
7.9 kg at month 24 (p < 0.001). However, there was no
significant difference in gaining weights between the
intervention and control groups (50.2 ± 6.8 vs 50.3 ±
7.7 kg at baseline, respectively; p = 0.86 and 53.5 ± 7.0 vs
53.9 ± 8.8 kg at month 24, respectively; p =0.66). There
were 163 (25%) patients who had to change their treat-
ment regimens due to ADRs, of which the most com-
mon reasons for changing the regimens were peripheral
neuropathy (104; 64%), rash (25; 15%), hepatitis (15; 9%)
or TB treatment (9; 6%). However, there was no signifi-
cant difference between the intervention and control
groups (89; 27% vs 74; 24%, p = 0.47). Fifty-four patients
(8.5%) developed at least one OI or TB after 6 months
of ART (8% in the intervention group and 9% in the
control). Six (1%) patients switched to second-line
Table 1 Number of patients in each cluster enrolled in either
the intervention or control groups
Intervention communes Nr patients Control communes Nr patients
Yet Kieu 16 Tran Hung Dao 30
Bach Dang 25 Hon Gai 26
Cao Xanh 46 Hung Thang 6
Hong Hai 26 Cao Thang 32
Bai Chay 23 Ha Lam 42
Dai Yen 7 Ha Tu 23
Ha Khanh 13 Ha Khau 20
Ha Phong 13 Hong Ha 21
Tuan Chau 7 Viet Hung 9
Gieng Day 15 Ha Trung 18
Thanh Son 16 Bac Son 4
Quang Trung 21 Phuong Dong 8
Phuong Nam 3 Dien Cong 1
Vang Danh 10 Trung Vuong 13
Thuong Yen Cong 1 Nam Khe 4
Mao Khe 44 Yen Thanh 6
Yen Duc 1 Dong Trieu 3
Kim Son 4 Tan Viet 1
Hung Dao 1 Thuy An 1
Xuan Son 1 Yen Tho 4
Binh Khe 1 Hoang Que 6
Viet Dan 1 Hiep Hoa 2
Binh Duong 3 Lien Vi 4
Quang Yen 8 Cong Hoa 8
Yen Giang 2 Ha An 5
Hoang Tan 1 Cam La 1
Yen Hai 4 Dong Mai 1
Minh Thanh 6 Phong Hai 6
Nam Hoa 4 Phong Coc 3
Lien Hoa 9 0
Total (I & C) 332 308
Total nr patients 640
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regimens (3 in the intervention group and 3 in the con-
trol); all of these switched after treatment and at least
18 months after having confirmatory PCR VL >5000
copies/ml. The overall mortality risk was 11% with no
significant difference between the intervention and con-
trol group (results not shown). Based on the monitoring
during OPC visits no case of peer-support induced
stigmatization was detected during the study.
Virologic failure
After 24 months of ART initiation, a total of 46 patients
(7.2%) experienced virologic failure. There was no signifi-
cant difference regarding virologic failure risks between the
intervention (cumulative virologic failure at 24 months
equal to 23/332; 6.9%) and control groups (23/308, 7.5%) at
any time point (6, 12, 18, or 24 months) (Table 3). Of the
46 virologic failure cases, 22 (48%) were primary virologic
failure. The Kaplan-Meier curves showed no significant dif-
ference in time to virologic failure between the intervention
and control group (Log-rank p-value = 0.77) (Fig. 2).
The adjusted results from the Cox proportional hazards
frailty model showed that the significant risk factors for de-
veloping virologic failure were ART-non-naïve status [aHR
7.0;(95% CI 3.3–14.7); p < 0.01]; baseline VL ≥100,000 cop-
ies/ml [aHR 2.3;(95% CI: 1.2–4.3); p < 0.05], and incomplete
adherence [aHR 3.1;(95% CI: 1.1–8.9); p < 0.05] (Table 4).
There was no significant effect of intervention on time
to virologic failure.
After excluding the 35 ART-non-naïve patients, the
statistical analysis among only 605 naïve patients (316 in
the intervention group and 289 in the control group)
also showed no significant difference in virologic failure
risks between intervention and control group [6.3%
vs 5.2%; respectively, RR = 1.22; (95% CI: 0.63–2.37);
p = 0.56] (data not shown).
Immunologic outcome
The median CD4 counts increased rapidly from 83 cells/
μl (IQR 29–176) at baseline to 202 cells/μl (IQR 121–
311) at month 6, to 260 cells/μl (IQR 168–400) at month
Fig. 1 Patient recruitment and outcome status after 24 months of follow-up
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Table 2 Demographic and clinical characteristics of 640 patients enrolled in both the intervention and control groups
Variables Total (n = 640) Control (n = 308) Intervention (n = 332) P-value**
n (%) n (%) n (%)
Age Median (IQR) 31.9 (28.2–35.1) 31.7 (28.2–34.5) 32.1 (28.4–35.6)
<35 years old 474 (74.1) 235 (76.3) 239 (72.0) 0.21
≥35 years old 166 (25.9) 73 (23.7) 93 (28.0)
Sex Male 452 (70.6) 216 (70.1) 236 (71.1) 0.79
Female 188 (29.4) 92 (29.9) 96 (28.9)
Marital status Single 195 (30.5) 89 (28.9) 106 (32.0) 0.44
Married/divorced 445 (69.5) 219 (71.7) 226 (68.1)
ART-naïve status Naïve 606 (94.7) 289 (45.2) 317 (49.5) 0.35
Non-naïve 35 (6.0) 19 (6.2) 16 (4.8)
History of OIs* Yes 182 (28.4) 91 (29.5) 91 (27.4) 0.55
No 458 (71.6) 217 (70.5) 241 (72.6)
Occupation Employed 493 (77.0) 243 (78.9) 250 (75.3) 0.31
Unemployed 147 (23.0) 65 (21.1) 82 (24.7)
Time to be known infected ≥6 months <6 months HIV- 156 (24.4) 69 (22.4) 87 (26.2) 0.31
449 (70.0) 220 (71.0) 229 (69.0)
HIV transmission route (self-reported) IV Drug use 297 (46.4) 136 (44.2) 161 (48.5) 0.27
Sexual and others 343 (53.6) 172 (55.8) 171 (51.5)
History of IDU Yes 337 (52.7) 151 (49.0) 186 (56.0) 0.08
No 303 (47.3) 157 (51.0) 146 (44.0)
Viral hepatitis Yes 207 (33.7) 92 (31.1) 115 (36.2) 0.18
No 407 (36.3) 204 (68.9) 203 (63.8)
History of TB Yes treatment 99 (15.5) 53 (17.2) 46 (13.9) 0.24
No 541 (84.5) 255 (82.8) 286 (86.1)
Having an HIV infected family member Yes 256 (40.0) 132 (42.9) 124 (37.3) 0.09
No 384 (60) 176 (57.1) 208 (62.7)
WHO clinical stage Clinical stage 1 or 2 298 (46.6) 142 (46.1) 156 (47.0) 0.82
Clinical stage 3 or 4 342 (53.4) 166 (53.9) 176 (53.0)
BMI” 18+ kg/m2 409 (64.0) 188 (61.0) 221 (66.7) 0.15
<18 kg/m2 231 (36.0) 120 (39.0) 111 (33.3)
Hemoglobin level <100 g/L 73 (11.4) 33 (10.7) 40 (12.0) 0.61
≥100 g/L 520 (81.2) 253 (82.1) 267 (80.4)
CD4 counts Median (IQR) 83 (29–176) 82 (27–183) 84 (30–168) 0.90
<100 cells/μl 359 (56.1) 172 (55.8) 187 (56.3)
>100 cells/μl 281 (43.9) 136 (44.2) 145 (43.7)
VL at baseline (copies/ml) <100.000 426 (66.7) 209 (67.9) 217 (65.6) 0.54
≥100,000 213 (33.3) 99 (32.1) 114 (34.4)
regimen D4T/3TC/NVP ART^ 533 (83.3) 258 (83.8) 275 (82.8) 0.75
Other regimens 107 (16.7) 50 (16.2) 57 (17.2)
Clinics Halong CDC 307 (48.0) 168 (54.5) 139 (41.9) 0.001
Other clinics 333 (52.0) 140 (45.5) 193 (58.1)
*OIs opportunistic infections, IDU Injecting drug use, TB tuberculosis, BMI Body Mass Index, ART Antiretroviral therapy, VL viral load
**Chi-square test
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12, to 305 cells/μl (IQR 220–463) at month 18 and to
371 cells/μl (IQR 249–534) at month 24 (Fig. 3). The in-
crease of median CD4 count from baseline to month 24
was 286 cells/μl (292 cells/μl in the intervention group
and 279 cells/μl in the control group).
Patients with baseline VL ≥100,000 copies/ml
[adj.sq.coeff. (95% CI): −0.9 (−1.5;−0.3); p < 0.01] and
baseline CD4 count <100 cells/μl [adj.sq.coeff. (95%
CI): −5.7 (−6.3;−5.1); p < 0.01] had a significantly
lower increase of CD4 count compared to the other
patients. On the other hand, patients with an HIV-
infected family member had a significantly higher in-
crease in CD4 count compared to those who did not
have an HIV-infected family member [adj.sq.coeff.
(95% CI): 1.3 (0.8;1.9); p < 0.01] (Tables 4 and 5).
The results showed no significant effect of the inter-
vention on the evolution of CD4 count trend between
the intervention and control groups.
Discussion virologic failure, mortality and
retention rates
To our knowledge, this is the first randomized con-
trolled trial study in Vietnam to assess the impact of
peer support on virologic and CD4 outcomes among
HIV-infected patients starting ART. Our study showed a
comparably low virologic failure risk, low mortality and
high retention rate after 24 months of follow-up. This
indicates that a well-funded and organized ART program
implemented through PEPFAR and Global Fund in
Vietnam can be rolled out successfully in remote and
resource-limited settings.
After 24 months follow-up, the virologic failure risk in
our study (7.2%) was lower than anticipated when the
study was planned and compared to other countries (15
to 20%) [30–33]. This, in retrospect, may have made the
study underpowered. Among the 46 virologic failure
cases in our study, 22 (48%) were secondary virologic
failure (10 in the intervention group and 12 in the con-
trol group). In Sub-Saharan African countries, findings
from systematic reviews showed an overall virologic fail-
ure risk (VL >1000 copies/ml) was 24% within 12 months
of ART [34] and 15% after 24 months of ART [34], the
highest risk (43%) was seen in a Rwanda [35].
In our study, the proportion of virologically suppressed
patients on ART at 24 months was 94% which is higher
than those reported from other resource-constrained set-
tings including Uganda (86%) [36], Malawi (84%) [37] and
Cameroon (52%) [38]. Studies in Vietnam reported that the
proportion of patients with viral suppression among IDU
populations were 73% [39] and 70% in Ho Chi Minh City
[18]. In neighboring Cambodia, 88% (306/346) of patients
had achieved VL <400 copies/ml [40] and in Thailand, 15%
(55/345) had virologic failure (>400 copies/ml) at 24 months
[41]. However, most of these studies reported ontreatment
results that were analyzed in a cross-sectional fashion and
included both ARTnaïve and non-naïve patients. The good
treatment outcome in our study may be explained by
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Fig. 2 Log-rank test for equality of survival curves between intervention
and control group (Log-rank p= 0.77)
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several factors including that the vast majority of patients
were ART-naïve and the VL results were reported to the
treating doctors since knowledge about viremia may result
in intensification of the adherence support, both for inter-
vention and control group patients.
Despite the fact that the majority of the patients were
severely immune-suppressed with low CD4 counts at
baseline and half were reported to be at clinical stage 3
or 4, our study showed a lower mortality risk (11% or
6.4/100 person-years) compared to other studies in
resourcelimited countries [36–38, 42–44]. However, the
mortality risk of this study was higher than that of stud-
ies in middle- and high-income countries [45–47]. The
survival and causes of death among patients in our
cohort was previously reported [48].
The retention rate of patients on ART was 78% after
24 months with no significant difference between the inter-
vention and control groups (p = 0.7). High retention rates
in care indicate not only an improved health care system
and ART programs in Vietnam, but also effective care and
support activities in the community to motivate and engage
patients in care. A recent study in Vietnam conducted
among 4531 adults and 313 children showed that 81.2 and
84.4%, respectively, were still on ART after 12 months [49].
This result was similar with the retention rate in Thailand
(80.8% after 5 years) [45], Cambodia (80% after 4 years)
[43] and higher compared to studies in sub-Saharan Africa
with 24 months of follow-up: Uganda (72%) [36] and
Malawi (66%) [37]. Other studies also showed that engage-
ment of HIV care is associated with improved clinical, vi-
rologic and immunologic parameters and survival
outcomes [50, 51]. Therefore, retaining HIV-infected pa-
tients in care has become a public health issue to ensure
the success and sustainability of ART programs [52].
Immunologic outcomes
As shown in our study, CD4 counts responded well after
24 months of ART (overall increase of 286 cells/μl). This
finding is in line with other studies that show how CD4 cell
counts increased quickly, in particular after 6 months of
ART [38, 53]. However, there was no significant difference
between the intervention and control groups in CD4 trends
after the adjustment (p = 0.69). Factors that predict the in-
crease of CD4 counts were the VL at baseline ≥100,000
Table 4 Virologic failure risk analyzed with bivariate and adjusted HRs of Cox proportional hazards frailty model
Bivariate Adjusted
Characteristics HR (95% CI) p-value aHR (95% CI) p-value
Intervention group 1.0 (0.5;1.7) 0.94
Male gender 2.0 (0.1;4.0) 0.05
Age <35 years 0.7 (0.4;1.4) 0.37
Severe HIV (clinical stage 3 or 4) 1.2 (0.6;2.1) 0.59
History of IDU 1.9 (1.0;3.3) 0.04
ART-non-naïve status 4.8 (2.4;9.4) <0.01 7.0 (3.3–14.7) <0.01
TB history 1.6 (0.8;3.2) 0.15
VL at baseline ≥100,000 copies/ml 1.6 (0.9;2.8) 0.13 2.3 (1.2–4.3) <0.05
CD4 at baseline < 100 cells/μl 1.4 (0.8;2.5) 0.28
Having an HIV-infected family member 0.5 (0.3;0.9) 0.03
From Ha long OPC 1.0 (0.6;1.8) 0.91
History of OIs 0.5 (0.2;1.0) 0.06
Changed ART regimen 1.1 (0.5;−2.0) 0.85
Incomplete adherence 2.4 (0.9;6.7) 0.09 3.1 (1.1–8.9) <0.05
OIs opportunistic infections, VL viral load, IDU Injecting drug use, TB tuberculosis, ART Antiretroviral therapy, OPC outpatient clinic, HR Hazard Ratio, aHR adjusted
Hazard Ratio
The boldface indicates significant (p<0,05) result
Fig. 3 Median trends of CD4 counts over time between intervention
and control groups
Cuong et al. BMC Infectious Diseases  (2016) 16:759 Page 10 of 14
copies/ml, a baseline of CD4 counts <100 cells/μl, and hav-
ing an HIV-infected family member. In a study in Thailand,
CD4 count at baseline and changes in CD4 count were
important in predicting CD4 counts ≤200 cells/μl [54].
In our study, after 24 months we found 45 patients
(7%) had immunologic failure, of whom 23 (6.9%) were
in the intervention group and 22 (7.1%) in the control
group (no significant difference, p >0.05). Also, there
was a high discordance (71%) between immunologic and
virologic failure. Only 13 patients (29%) had both
immunologic failure and virologic failure (p <0.001).
Factors associated with virologic failure
Our study showed that ART-non-naïve status, high base-
line VL (≥100,000 copies/ml) and incomplete adherence
(missing more than one dose during 24 months) were
risk factors for virologic failure. High VL (>100,000 cop-
ies/ml) at baseline can be a predictor for the slower in-
crease of CD4 counts and mortality [48]. Therefore, our
findings were in line with other studies that high VL at
baseline is a predictor for virologic failure and mortality
during ART [18, 55, 56]. Contrarily, studies in Thailand
shows low baseline CD4 count and race/ethnicity were
independent predictors of virologic response, however
baseline VL and gender were not [54]. Also, univariate
analysis showed having a child was significantly associ-
ated with lower virologic failure risk [41].
Impact of peer support intervention
The study results might answer the research question in
that there was no significant difference between the
intervention and control groups in both cumulative viro-
logic failure risk and time to virologic failure after 2
years of follow-up. This result could be explained in sev-
eral ways. While the simplest explanation is that peer
support inherently does not affect treatment outcomes,
we cannot exclude the possibility that our sample sizes
may simply have been insufficiently large. With a larger
study, we might have been able to gain enough statistical
power to discern a difference between the intervention
and control groups. Also, the adherence is self-reported,
and may have been affected by observer bias. Also, the
ART program in Vietnam has been well funded and
implemented through international donors including
PEPFAR and Global Fund. Before ART was initiated,
each patient had to be assessed for ART readiness, name
a supporting family member and attend three adherence
counseling sessions according to the National Guidelines
[22]. Furthermore, the eventual effect of the intervention
might also be masked by a “ceiling effect” in which the
control group also received a sufficient baseline adher-
ence support. Free ARV may have also contributed to
this “ceiling effect”. The baseline support may have been
at such a high level that additional support did not affect
treatment outcomes.
In addition, patient support could have originated from
a number of different sources that may have contaminated
the study including the OPCs and the community-based
programs. Quang Ninh province, with a comparably high
HIV prevalence, was receiving PEPFAR support in order
to set up “comprehensive care, treatment and support”
programs with NGOs, which were very active during the
Table 5 Effect of predictors and evolution of CD4 cell count on HIV infected patients on ART
Bivariate Adjusted
Characteristics Coeff (95% CI) p-value Adj.sq.Coeff (95% CI) p-value
Intervention group 0.2 (−0.6;−0.9) 0.69
Female gender −3.0 (−3.8;−2.3) <0.001
Age <35 years −0.3 (−1.1;−0.6) 0.54
Severe HIV (clinical stage 3 or 4) −2.1 (−2.8;−1.4) <0.001
History of IDU −2.1 (−2.8;−1.4) <0.001
ART-non-naïve status 0.8 (−0.8;2.5) 0.32
TB history −0.2 (−1.2;0.8) 0.68
VL at baseline ≥100,000 copies/ml −2.8 (−3.6;−2.0) <0.001 −0.9 (−1.5;−0.3) <0.01
CD4 at baseline <100 cells/μl −6.8 (−7.4;−6.3) <0.001 −5.7 (−6.3;−5.1) <0.001
Having an HIV-infected family member 2.5 (1.8;3.3) <0.001 1.3 (0.8;1.9) <0.001
From Ha long CDC OPC −0.5 (−1.2;0.3) 0.22
History of OIs 1.1 (0.3;1.9) <0.01
Changed ART regimen 1.0 (0.1;1.8) <0.05
Incomplete adherence (missing more than one doses in 24 months) −1.3 (−3.1;0.5) 0.15
Month 0.4 (0.4;0.4) <0.001 0.39 (0.38;0.41) <0.001
OIs opportunistic infections, VL viral load, IDU Injecting drug use, TB tuberculosis, ART Antiretroviral therapy, OPC outpatient clinic, Coeff Coefficient, adj.sq.Coeff
adjusted square Coefficient
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time of the project implementation. The availability of
community-based activities provided by “the Bright Fu-
ture” and other community outreach groups might have
constituted a “contamination” where patients in the inter-
vention group could meet and share adherence experi-
ences with patients in the control group.
Furthermore, IDU in both the control and interven-
tion groups had incentives to remain on the treatment
regimens. Active IDUs may get arrested and placed into
a drug rehabilitation centers. The risk of this may be in-
creased if they fail to follow the treatment schedule, and
thereby get attention from authorities. IDUs also re-
ceived further counseling at the OPC and, for those in
the intervention group, from the peer supporters.
In our study, 400 (63%) patients lived with their parents
and other family members who might also play an import-
ant role as “internal supporters” to support patients in
taking ARVs. Vietnamese culture strongly values the care
of the extended family members, so most patients had
good support for adherence from their families.
In our study, we only reported data to the 24-month-
follow-up; hence the sustained or longterm effect of the
adherence support intervention cannot be excluded. It
should be noted that as patients started their ARV and
improved their health, their perceived need for peer
support may have declined. It was also apparent from
discussion with peer supporters and patients that the
personal relationship between the patient and supporter
was crucial for long term peer support and follow up.
Many patients saw the benefit and developed a close
bound to their peer supporter, sometimes too close from
the peer supporter’s point of view. In other cases, the pa-
tients perceived the support as an annoyance. A recent
study in Uganda has also shown that peer health care
intervention had no impact on cumulative risk of viro-
logic failure and virologic outcomes on short-term ART
and suggested that it might be best suited for patients
who have taken ART for longer periods, especially as it
may mitigate the effects of “treatment fatigue” as patients
tire of continually taking ART [13]. Therefore, to assess
the sustained effect of the peer support intervention in
our cohort, further research to continue following up
patients with VL and CD4 count monitoring up to at least
48 months is needed.
Despite the results showing peer support had no sig-
nificant effect on virologic failure, it is nevertheless clear
that good outcomes can be achieved in resource-limited
communities. The support the patients received may still
be considered a global standard of care.
Methodological considerations
This is the first cluster randomized controlled trial on
HIV conducted in a rural setting in Vietnam. We had
some limitations and constraints in logistics, in recruiting
patients, collecting data, and analysis due to a lack of pre-
cedence to follow. It took 2 years for recruiting enough
patients instead of 10 months that we had originally
planned. There were 35 (6%) patients who were ART-
non-naïve. However, as the study was intention-to-treat
and the non-naïve status was revealed after enrollment,
these cases were still included in the study and the results
might not represent whole treatment-naïve population.
Patients in both groups may receive other community-
based supports that might be a “contamination”. In
addition, patients in the intervention group could meet
and share adherence experiences with patients in the con-
trol group at the clinic (i.e., there were 2 couples of whom
the men in the intervention group married women in con-
trol group). Some patients were willing to move or even
travel long distances in order to receive treatment from a
certain clinic. This devotion to obtaining ARV could have
contributed to the high adherence in both groups. The
CD4 counts were done in two different hospital laborator-
ies which may bias the estimation of immunologic failure.
As the clusters were randomized before the recruitment
of patients and the selection process of the patients should
have randomized the individual clusters, the difference in
the number of patients in each arm is unlikely to lead
to bias. A limitation in our study was that the adher-
ence data collected from peer supporters during their
patient encounters in the intervention group wasn’t
included in the analyses.
Conclusions
ART programs in resource-limited rural settings like
Quang Ninh, Vietnam can provide an effective care and
treatment with a low virologic failure risk if the patients
are well-prepared for ART and followed up regularly by
an out-patient clinic. Peer support to improve adherence
did not show any impact on virologic failure and CD4
trends during first 2 years of ART. High VL at baseline
is a predictor for virologic failure and CD4 trends.
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